Survival analysis revealed that patients with HR+/HER2− BC exhibiting high TACSTD2 expression demonstrated significantly higher overall survival (OS), recurrence-free survival (RFS), and distant-RFS (OS Hazard ratio (HR) = 0.76, P = .0008; RFS HR = 0.64, P = .0001; and distant-RFS HR = 0.64, P = .0011; Figure 2). The gene discussed is TACSTD2; the disease is breast cancer.